Q-omics provides the consensus-scored RPL13AP23 profile across patient tissues and cancer cell-line models. RPL13AP23 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPL13AP23 is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, RPL13AP23 RNA expression shows 8,414 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, KICH, and ACC as cancer lineages where RPL13AP23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL13AP23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL13AP23 survival associations across molecular data types. RPL13AP23 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL13AP23 RNA expression–survival associations across cancer types. High RPL13AP23 expression shows unfavorable associations in KICH, OV, ACC and DLBC, but favorable associations in CESC and LUSC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RPL13AP23 RNA expression.
This table summarizes RPL13AP23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RPL13AP23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL13AP23 shows lower tumor expression in BRCA and higher tumor expression in KICH, COAD, THCA, CHOL and LIHC. The KICH box plot shows higher RPL13AP23 RNA expression in tumor versus normal tissue (log2 FC = +0.425, t-test p = .005).
This table shows molecular features associated with RPL13AP23 in patient tissues and cancer cell lines. In patient samples, RPL13AP23 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
